Analysis of a case of 5-hydroxytryptamine syndrome caused by oxycodone hydrochloride sustained-release tablets
10.12173/j.issn.1005-0698.202503005
- VernacularTitle:盐酸羟考酮缓释片致5-羟色胺综合征1例分析
- Author:
Mengyu ZHANG
1
;
Xiaomin XING
;
Jikai WANG
;
Jinfeng LI
;
Yuan ZHANG
;
Fanbo JING
Author Information
1. 山东大学附属威海市立医院药剂科(山东 威海 264200)
- Publication Type:Journal Article
- Keywords:
Oxycodone hydrochloride sustained-release tablets;
5-Hydroxytryptamine Syndrome;
Morphine sulfate sustained-release tablets;
Adverse drug reaction
- From:
Chinese Journal of Pharmacoepidemiology
2025;34(6):715-719
- CountryChina
- Language:Chinese
-
Abstract:
One female patient with cancer pain due to bone metastasis from breast cancer was initially treated with Xinhuang tablets,diclofenac sodium double-release enteric-soluble capsules,paracetamol dihydrocodeine tablets and paracetamol oxycodone tablets,before being switched to controlled-release oxycodone hydrochloride tablets.She regularly took oxycodone hydrochloride sustained-release tablets 20 mg,q12h,no abnormalities were observed,and the dosage was increased to 40 mg,q12h due to poor pain control.The patient was diagnosed with 5-hydroxytryptamine syndrome after 1 d of intermittent recurrent tremor,myotonia,scalp sweating,restlessness and elevated blood pressure.When oxycodone hydrochloride sustained release tablet was adjusted to 20 mg,q12h and gabapentin capsule was added to 0.1 g,tid,the frequency of tremor and myotonia attacks slightly decreased,and sweating and agitation symptoms were not relieved.After 14 days,oxycodone hydrochloride sustained release tablets were stopped and morphine sulfate sustained release tablets 60 mg,q12h were replaced.Three days later,the patient's symptoms disappeared.During 5-month follow-up,the patient's pain was well-contrdled,with no change in the dose of morphine sulfate sustained-release tablets,and no adverse drug reactions observed.Using the Naranjo's Assessment Scale,the association between the patient's serotonin syndrome and the suspected drug oxycodone hydrochloride sustained-release tablets was evaluated as"probable".Thiscase highlights the importance for clinicians to closely monitor adverse reactions induced by rapid opioid dose escalation to ensure medication safety in patients.
